APA

Augeri D. J., Robl J. A., Betebenner D. A., Magnin D. R., Khanna A., Robertson J. G., Wang A., Simpkins L. M., Taunk P., Huang Q., Han S., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G. E., Egan D. M., Marcinkeviciene J., Chang S. Y., Biller S. A., Kirby M. S., Parker R. A. & Hamann L. G. (20050823). Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. : Journal of medicinal chemistry.

Chicago

Augeri David J, Robl Jeffrey A, Betebenner David A, Magnin David R, Khanna Ashish, Robertson James G, Wang Aiying, Simpkins Ligaya M, Taunk Prakash, Huang Qi, Han Song-Ping, Abboa-Offei Benoni, Cap Michael, Xin Li, Tao Li, Tozzo Effie, Welzel Gustav E, Egan Donald M, Marcinkeviciene Jovita, Chang Shu Y, Biller Scott A, Kirby Mark S, Parker Rex A and Hamann Lawrence G. 20050823. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. : Journal of medicinal chemistry.

Harvard

Augeri D. J., Robl J. A., Betebenner D. A., Magnin D. R., Khanna A., Robertson J. G., Wang A., Simpkins L. M., Taunk P., Huang Q., Han S., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G. E., Egan D. M., Marcinkeviciene J., Chang S. Y., Biller S. A., Kirby M. S., Parker R. A. and Hamann L. G. (20050823). Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. : Journal of medicinal chemistry.

MLA

Augeri David J, Robl Jeffrey A, Betebenner David A, Magnin David R, Khanna Ashish, Robertson James G, Wang Aiying, Simpkins Ligaya M, Taunk Prakash, Huang Qi, Han Song-Ping, Abboa-Offei Benoni, Cap Michael, Xin Li, Tao Li, Tozzo Effie, Welzel Gustav E, Egan Donald M, Marcinkeviciene Jovita, Chang Shu Y, Biller Scott A, Kirby Mark S, Parker Rex A and Hamann Lawrence G. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. : Journal of medicinal chemistry. 20050823.